

Keynote Address



The program will feature a keynote address by Leroy Hood, MD, PhD, an internationally renowned scientist and pioneer in personalized medicine, who founded the Institute of Systems Biology in Seattle.

Welcome

John Maupin, DDS, MBA President, Morehouse School of Medicine

Proclamation & Opening Remarks

Governor Nathan Deal will proclaim Sept 1, 2011, as Personalized Medicine Awareness Day in Georgia and kick off a half-day program to mark the occasion at Morehouse School of Medicine.

Remarks: The Honorable **Andrew Young,** Former UN Ambassador



Panel Discussion Featuring

Valerie Montgomery Rice, MD

Dean and Executive Vice President of Morehouse School of Medicine

David Satcher, MD, PhD

Director of the Satcher Health Leadership Institute at Morehouse School of Medicine and the 16th Surgeon General of the United States

Kenneth L. Brigham, MD

Associate Vice President and Director of the Predictive Health Institute at Emory University and Georgia Institute of Technology

Elizabeth Ofili, MD, MPH

Associate Dean and Director of the Clinical Research Center at Morehouse School of Medicine, national principal investigator of the WARFARIN study, a first of its kind personalized medicine study approved by the Centers for Medicare and Medicaid Services

Roger Simon, MD

Director of Translational Programs in Stroke and Professor of Neurology and Neurobiology at Morehouse School of Medicine

David Stephens, MD

Vice President of Research at Emory University's Woodruff Health Sciences Center

Fred Sanfilippo, MD, PhD

Director of the Emory University and Georgia Institute of Technology Healthcare Innovation Program

September 1, 2011 Event: 1pm - 4pm

Louis W. Sullivan National Center for Primary Care Morehouse School of Medicine 720 Westview Dr SW, Atlanta, GA

Cocktail Reception: 4-5pm

Louis W. Sullivan National Center for Primary Care E. Ginger Sullivan Atrium













The program is being organized by Morehouse School of Medicine, Emory University and Georgia Institute of Technology, all of which participate in an NIH-funded consortium called the Atlanta Clinical and Translational Science Institute (ACTSI). Georgia Bio is a partner of ACTSI and is participating in the program, along with Iverson Genetic Diagnostics. Iverson has a collaboration with Morehouse and ACTSI in a clinical research study of a new technology that will make the practice of personalized medicine possible. Georgia's healthcare institutions are leading sites for the study.